JNJ Jan 2026 230.000 put
| Previous close | 84.18 |
| Open | 84.18 |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 230.00 |
| Expiry date | 2026-01-16 |
| Day's range | 84.18 - 84.18 |
| Contract range | N/A |
| Volume | |
| Open interest | 1 |
Associated Press FinanceJ&J subsidiary proposes paying about $6.48B over 25 years to settle talc ovarian cancer lawsuits
A subsidiary of Johnson & Johnson is now proposing to pay approximately $6.48 billion over 25 years as part of a settlement in the U.S. to cover allegations that its baby powder containing talc caused ovarian cancer. The lawsuits filed against J&J had alleged its talcum powder caused users to develop ovarian cancer, through use for feminine hygiene, or mesothelioma, a cancer that strikes the lungs and other organs. The claims contributed to drop in J&J’s sales of baby powder, prompting the company to stop selling its talc-based products in 2020.
BloombergJ&J Seeks Backing for $11 Billion Baby Powder Cancer Deal
(Bloomberg) -- Johnson & Johnson will ask thousands of people suing over its allegedly tainted baby powder to vote in favor of a settlement that would allow the company to resolve all litigation for $11 billion — $2.1 billion more than it offered last year.Most Read from BloombergTesla Axes Supercharger Team in Blow to Broader EV MarketNYC Police Break Up Columbia Protest and Clashes Erupt at UCLALilly Soars as Forecast Boost Shows Weight-Loss Drugs’ PowerAmazon Posts Strongest Cloud Sales Growt
ReutersJ&J advances $6.475 billion settlement of talc cancer lawsuits
Johnson & Johnson is moving forward with a $6.475 billion proposed settlement of tens of thousands of lawsuits alleging that its baby powder and other talc products contain asbestos and cause ovarian cancer, the company said Wednesday in a statement. The deal would allow it to resolve the lawsuits through a third bankruptcy filing of a subsidiary company. It will begin a three month voting period in hopes of reaching consensus on a settlement of all current and future ovarian cancer claims.
